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Background: To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the pharmaco-
kinetics of raltegravir and lamivudine in genital tissue against ex vivo tissue infection with HIV-1.
Methods: Open-label trial of 36 HIV-negative females and males randomized to 7 days raltegravir 400 mg twice
daily and 7 days raltegravir 400 mg!lamivudine 150 mg twice daily (after washout), or vice versa. Blood, saliva,
rectal fluid, rectal tissue, vaginal fluid and vaginal tissue were sampled at baseline and on and off PrEP during a
total of 12 days, for pharmacokinetics and antiviral activity via ex vivo HIV-1BaL challenge. Ex vivo infectivity was
compared with baseline. The trial has been registered in https://clinicaltrials.gov/ with the identifier
NCT03205566.
Results: Steady state for both drugs was reached by day 4. Dosing with raltegravir alone provided modest ex
vivo HIV protection with higher drug levels in rectal tissue and vaginal tissue than in plasma on and off PrEP. Off
PrEP, plasma and vaginal concentrations declined rapidly, while persisting in the rectum. On PrEP, the highest la-
mivudine concentrations were in the rectum, followed by vaginal tissue then plasma. Lamivudine washout was
rapid in plasma, while persisting in the rectum and vagina. Raltegravir/lamivudine increased ex vivo protection
on and off PrEP compared with raltegravir alone, reaching maximum protection at day 2 in rectal tissue and at
day 8 in vaginal tissue.
Conclusions: Raltegravir 400 mg!lamivudine 150 mg showed high levels of ex vivo HIV protection, associated
with high drug concentrations persisting after discontinuation in vaginal and rectal compartments, supporting
further investigation of these agents for PrEP.
Introduction
Oral pre-exposure prophylaxis (PrEP) is a rapidly emerging preven-
tion strategy that could help reduce HIV incidence globally.1–4
The use of daily and on-demand oral Truvada (tenofovir disoproxil
fumarate/emtricitabine), a combination of two NRTIs, for PrEP has
demonstrated high efficacy.1–3 However, its use may be limited by
side effects, renal/bone toxicity and emerging drug resistance
globally.2,5,6 Furthermore, the use of PrEP agents acting at different
stages of the viral replication cycle may allow a more forgiving
dosing strategy than a regimen consisting of two NRTIs.
Integrase inhibitors act late in the replication cycle and their
role in PrEP is being explored as long-acting injectables.7
Raltegravir is well tolerated, has few drug–drug interactions8 and is
available as a generic drug in some countries. Humanized mice
models have shown that oral dosing with raltegravir prevents
HIV-1 vaginal transmission9 and penetrates well in vaginal and
gut tissues.10 In humans, raltegravir rapidly and extensively pene-
trates the female genital tract and colorectal tissue following oral
dosing with higher plateau levels compared with plasma.11–14
However, it is not known whether raltegravir tissue penetration is
sufficient to provide protection against vaginal or rectal
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transmission of HIV-1 or whether combination of raltegravir with
another antiretroviral such as lamivudine, an NRTI, is required.
Drug efficacy in preventing mucosal transmission can be
assessed by ex vivo challenge of mucosal tissue explants and has
been used to evaluate PrEP strategies15–18 in vivo in non-human
primate studies19–21 and clinical trials.22–27 The ex vivo challenge
approach allows evaluation of efficacy, proof of concept and in-
sight into adherence requirements for oral PrEP agents, providing
milestone data before embarking on large-scale efficacy studies,
which can be used as licensing data should efficacy be shown.
Despite the variety of models, consistent results can be obtained
among different laboratories through protocol standardization.28
This proof-of-concept study was undertaken to define the phar-
macokinetic (PK) and pharmacodynamic (PD) activity of raltegravir
using ex vivo HIV-1BaL-treated vaginal and rectal tissue obtained
from healthy men and women receiving a 7 day course of raltegra-




Thirty-six HIV-negative men (n = 18) and women (n = 18), with no sexually
transmitted infections, were randomized according to gender in this open-
label, PK/PD trial to one of six arms: A1, A2, A3, B1, B2 and B3 (Figure 1). The re-
sult being 6 women and 6 men per sampling arm and participants were
their own controls. Arm A (A1, A2 and A3) received 7 days of raltegravir
400 mg twice daily, followed by a 1 month washout and then 7 days of ral-
tegravir 400 mg/lamivudine 150 mg twice daily. Arm B (B1, B2 and B3)
started with 7 days raltegravir 400 mg/lamivudine 150 mg twice daily, had
a 1 month washout and then received 7 days of raltegravir 400 mg twice
daily.
Staggered sampling was undertaken at baseline, three timepoints on
PrEP and two timepoints in the 5 days after PrEP cessation according to
randomization arm. Sampling took place 12 h ± 30 min after PrEP dosing.
Collected samples were blood, saliva (by SalivetteV
R
), rectal fluid and vaginal
fluid (by Weck-Cel sponges; Weck-Cel surgical spear; Medtronic
Ophthalmic, Jacksonville, FL, USA), and rectal tissue and vaginal tissue
(by Sarratt biopsy forceps obtaining five 3 mm%3 mm%1 mm biopsies).
Biopsies were frozen for PK analysis or transported immediately in DMEM
(median time = 30 min) to the laboratory on ice for ex vivo PD assays.
Progesterone levels were measured on sampling visits for women.
Baseline biopsies were obtained from each individual as a control of ex
vivo challenge. Lack of productive infection of baseline biopsies resulted in
exclusion of data obtained from subsequent biopsies during the trial.
Sampling from women avoided menstruation and targeted the luteal
phase of the menstrual cycle.
The study was approved by the National Research Ethics Service
(ref: 17/LO/0094) and registered on https://clinicaltrials.gov/ct2/show/
NCT03205566?term=r-prep&cond=Hiv&rank=1. All subjects provided writ-
ten informed consent.
PK analysis
Drug concentrations in all matrices were measured by LC-MS/MS.29
Chromatographic separation of raltegravir and lamivudine was achieved
using a Synergi polar RP column. Stable isotope-labelled internal standards
(raltegravir-d6, 15N2
13C-lamivudine and 13C-tenofovir diphosphate) were
used for all methods. Bioanalytical method validation was carried out in ac-
cordance with FDA and EMA guidelines.30
Plasma and tissues
Drug was extracted by protein precipitation [in acetonitrile/water (5:1, v/v)].
Prior to extraction, tissues were homogenized using a MINILYS homogen-
izer and Precellys–Keramik kit (Bertin Technologies, Bordeaux). Calibration
curves ranged between 5–5000 ng/mL (plasma) and 0.35–1000 ng/mL
(tissue).
Lamivudine triphosphate (lamivudine-TP) tissue concentrations were
determined using weak anion exchange chromatography. Biopsies were
Figure 1. Study design. Two PrEP regimens were investigated and all 36 individuals (18 men and 18 women) received both regimens separated by a
1 month washout. Arm A started with 14 days of raltegravir 400 mg twice daily and arm B started with 14 days of raltegravir 400 mg!lamivudine
150 mg twice daily to remove sequential selection bias. Participants were randomized according to gender to one of six arms with three men and
three women per block (A1, A2, A3, B1, B2 and B3). bd, twice daily; 3TC, lamivudine.
Herrera et al.
2130
homogenized in a solution of methanol and 20 mM EDTA/EGTA (70:30, v/v).
A biobasic AX column with a pH gradient mobile phase was used to elute la-
mivudine-TP and detection was performed on an SCIEX 5500 triple quadru-
pole mass spectrometer. The assay was validated over the concentration
range of 0.075–213 pmol.
Saliva
Drug was extracted using solid phase extraction (SPE) [Oasis HLB (30 mg)]
cartridges. The solvent phase was evaporated and reconstituted in
acetonitrile/water (1:99, v/v). The calibration curve (0.5–50 ng/mL for both
analytes) was prepared using saliva collected from non-medicated healthy
volunteers using the SalivetteV
R
method.
Vaginal and rectal fluids
Drug was extracted from Weck-Cel sponges with a mixture of acetonitrile/
0.1% formic acid. The smples were then passed through SPE [Oasis HLB
(30 mg)] cartridges as an additional sample clean-up step. The solvent
phase was evaporated and reconstituted in acetonitrile/water (1:99, v/v).
The volume of fluid on each sponge was predetermined by subtracting the
weight of the ‘dry’ sponge prior to sample collection. The calibration curve
(0.15–200 ng/sample) was constructed by spiking plasma calibration
standards onto cellulose-based Weck-Cel sponges.
PD analysis
Susceptibility to HIV infection was assessed using an ex vivo challenge
model15,31 with a reference clade B R5-tropic isolate, HIV-1BaL,
32 provided
by the NIH AIDS Research & Reference Reagent Program (http://www.aids
reagent.org/). Vaginal and rectal biopsies were cut in explants, exposed in
duplicates for 2 h to HIV-1BaL at a high (10
4 TCID50/mL) and a low (10
2
TCID50/mL) titre and then washed with PBS. Different titres of virus were
used to mimic in vivo transmission. Rectal explants were transferred onto
gelfoam rafts (Pfizer, NY, USA) and vaginal explants onto a fresh culture
plate. Explants were cultured for 15 days. Approximately 50% of the culture
supernatant was harvested every 2–3 days and cultures re-fed with fresh
medium in the absence of drug. Viral replication was measured as p24
concentration (INNOTEST HIV antigen mAb; Fujirebio Europe, Belgium) in
culture supernatant at days 3, 7, 11 and 15.
Statistical analysis
Drug concentrations are expressed as ng/mL of plasma or saliva. Tissue
homogenate and genital/rectal fluid samples were quantified using an
ng/sample calibration curve and converted into ng/mL by adjusting for
recorded fluid volumes and tissue weights, assuming an equivalent density
for 1 g of tissue and 1 mL of fluid.
Summary statistics of absolute drug concentrations at each visit on
days 2, 4 and 6 (on PrEP) and days 8, 10 and 12 (off PrEP) are presented
using the arithmetic mean and SEM. Inter-participant variability in plasma
concentration following drug administration was assessed by measuring
the coefficient of variation (CV = SD/mean%100). Compartment-to-plasma
ratios (parameterCOMP/parameterPlasma) were derived at each visit using
detectable drug levels only.
Results
Demographics and safety
Thirty-six subjects (18 males and 18 females) were included in the
analysis (Table 1). The luteal phase could not be confirmed for all
female participants (Table S1, available as Supplementary data at
JAC Online). The study drugs were well tolerated with no serious
adverse events reported.
PK profile of raltegravir with or without lamivudine
Raltegravir and lamivudine were detectable at day 2 of PrEP and
concentrations reached steady state within 4 days of oral dosing in
Table 1. Baseline demographic characteristics; n = 36






black African 11 (30)
other 2 (6)
Weight (kg), mean ± SD 72.74 ± 13.8
BMI (kg/m2), mean ± SD 24.5 ± 3.60
Baseline characteristics are summarized as the mean ± SD (continuous
normally distributed variables), median (IQR) (non-normally distributed
variables) and frequency (%) (categorical variables).
Figure 2. Longitudinal PK analysis. Raltegravir (a and b) and lamivudine (c) levels were measured in vaginal fluid, rectal fluid, vaginal tissue, rectal tis-
sue, plasma and saliva at each sampling point during and after PrEP dosing with raltegravir 400 mg (a) and raltegravir 400 mg!lamivudine 150 mg (b
and c). Data are mean ± SEM. The dotted line indicates the timepoint when PrEP dosing stopped. RAL, raltegravir; 3TC, lamivudine; VF, vaginal fluid; RF,
rectal fluid; VT, vaginal tissue; RT; rectal tissue.
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all compartments: plasma, saliva, vaginal tissue, vaginal fluid,
rectal tissue and rectal fluid (Figure 2 and Table S2).
The PK profile of raltegravir was not significantly affected by
lamivudine when used in combination. Raltegravir was rapidly
absorbed into vaginal and rectal tissues. On day 2 of PrEP, raltegra-
vir plasma concentrations exceeded those in vaginal fluid and
vaginal tissue, suggesting a slight lag in raltegravir accumulation
in the female genital tract. Higher levels of raltegravir were
observed in the rectum than the female genital tract and
plasma. Raltegravir tissue-to-plasma ratios on PrEP were, on
average, 0.9 for vaginal tissue and 13 for rectal tissue. Off PrEP,
the ratios increased to 2.0 (vaginal tissue) and 128 (rectal tis-
sue). Raltegravir levels in rectal fluid were significantly higher
than rectal tissue during and after PrEP; however, in the vagina
the opposite was observed, with greater concentrations in
tissue than in secretions.
Raltegravir concentrations during PrEP in plasma, rectal and
vaginal samples were greater than the protein-adjusted IC95 for
WT virus (16 ng/mL)0.8 After PrEP cessation, 86% and 58% of rec-
tal tissue samples and 50% and 7% of vaginal tissue samples
remained above the IC95 at days 10 and 12, i.e. days 3 and 5 post-
ART, respectively, in both arms.
Rectal concentrations of lamivudine (Figure 2c) were higher on
average than vaginal and plasma concentrations. Lamivudine tis-
sue-to-plasma ratios were, on average, 8.0 for vaginal tissue and
129 for rectal tissue on PrEP and 17 (vaginal tissue) and 91 (rectal
tissue) off PrEP. Furthermore, lamivudine levels in the vaginal and
rectal compartments remained high after stopping PrEP, with
100% and 46% of rectal tissue samples and 60% and 43% of
vaginal tissue samples above the in vitro IC95 (183.4 ng/mL)
33 at
days 10 and 12, i.e. days 3 and 5 post-ART, respectively.
Average lamivudine-TP levels in vaginal tissue were 399 pmol/g
on PrEP and 305 pmol/g off PrEP (Table S3). Metabolite concentra-
tions persisted in vaginal tissue with 71% of vaginal tissue samples
detectable at day 12, i.e. day 5 post-ART. Lamivudine-TP was
undetectable in all rectal tissue samples.
Significant positive correlations were observed between ralte-
gravir and lamivudine concentrations in vaginal tissue and rectal
tissue with corresponding levels in plasma (Figure S1) and mucosal
secretions (Figure S2). In vaginal tissue, there was a significant log
relationship between lamivudine and lamivudine-TP concentra-
tions (P = 0.0171) (Figure S3a).
Saliva and plasma concentrations of raltegravir and lamivudine
were significantly correlated (r2>0.7; P < 0.0001) (Figure S1).
However, levels of raltegravir and lamivudine were lower in saliva,
accounting for approximately 4% (raltegravir) and 13% (lamivu-
dine) of total drug concentrations in plasma.
Sampling women rectally and vaginally simultaneously unique-
ly allowed comparison of compartments following oral dosing.
During oral dosing with raltegravir (both alone and in combination
with lamivudine), raltegravir levels in female rectal tissue were,
on average, 3.6 ± 0.4-fold higher than in vaginal tissue and
98.1 ± 24.8-fold higher in rectal fluid than in vaginal fluid at day 6.
Off PrEP, raltegravir levels remained high in the rectum, but began
to decline in the vaginal compartment, resulting in 76-fold higher
concentrations in rectal tissue than in vaginal tissue and 815-fold
higher concentrations in rectal fluid than in vaginal fluid at day 10,
i.e. day 3 post-ART (Figure S4). Similarly, lamivudine levels were
consistently higher in the rectum than in the vaginal compartment
of female subjects both on and off PrEP. Both raltegravir and lamiv-
udine concentrations in vaginal tissue significantly correlated with
levels in rectal tissue. For secretions, however, raltegravir vaginal
fluid significantly correlated with rectal fluid, but lamivudine did
not (Figure S4).
No significant gender differences were observed when compar-
ing the raltegravir and lamivudine plasma, saliva and rectal
concentrations (data not shown).
Efficacy of raltegravir and the raltegravir/lamivudine
combination against rectal and vaginal transmission
We evaluated the efficacy of oral PrEP in mucosal explants against
challenge with HIV-1BaL at two titres: a high titre routinely used to
obtain productive infection of explants and a low titre to mimic
in vivo transmission. For both titres, reductions in p24 levels com-
pared with those measured at baseline were observed in rectal tis-
sue and vaginal tissue after 2 days of oral dosing with raltegravir
alone and progressively decreased after PrEP cessation (Figure S5).
Dosing with the raltegravir/lamivudine combination resulted in a
greater reduction of p24 levels in both tissues (Figure S5). We then
used these reductions in p24 to define ex vivo protection as the
percentage of cultures where infectivity after ex vivo challenge
was reduced above a certain cut-off compared with baseline sam-
ples. We explored a range of cut-offs between 60% and 90%
(Figure 3 and Figure S6). For both dosing regimens, with 60%, 70%
or 80% cut-offs there was protection of rectal tissue and vaginal
tissue from day 2 on drug until 5 days post-drug cessation against
high and low titres. Using a 90% cut-off there was rectal, but not
vaginal, protection against high and low titre challenge across all
timepoints from day 2 on drug to day 5 post-drug cessation.
PK/PD correlation
Statistically significant inverse correlations between ex vivo
infectivity levels and drug concentrations were only observed in
participants dosed with raltegravir 400 mg!lamivudine 150 mg
between rectal tissue challenged with high viral titre and raltegra-
vir and lamivudine concentrations in plasma (Figure 4b and c) and
rectal tissue (Figure 4e and f). No significant PK/PD correlations
were observed with low viral titre challenge infectivity data
(Figure 4) or with lamivudine-TP levels in vaginal tissue (Figure S3b
and c).
Discussion
We showed that a 7 day course of raltegravir/lamivudine or ralte-
gravir alone results in high drug concentrations at multiple HIV
transmission sites by day 2 of dosing. Raltegravir concentrations
were consistently higher in the rectum than plasma, saliva and the
female genital tract. Higher levels of raltegravir in rectal fluid than
in vaginal fluid have also been reported in animal models and in
humans.12,34 Raltegravir persisted longest in rectal tissue and rec-
tal fluid in parallel with persistent ex vivo protection and resulting
in high rectal tissue-to-plasma ratios towards the end of the sam-
pling interval, as plasma concentrations declined. Vaginal tissue
and vaginal fluid raltegravir concentrations remained, on average,
above the in vitro IC95 for 3 days after dosing cessation, providing
protection levels above 70% with high and low ex vivo challenge
Herrera et al.
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titres. Interestingly, drug plasma levels correlated better with
those in vaginal tissue than in vaginal fluid and rectal samples.
Given that both drugs are metabolized via separate pathways,
not surprisingly, the raltegravir PK profile was not affected by the
combined dosing with lamivudine. Concentrations of lamivudine
and lamivudine-TP in the female genital compartment and in
the rectal tract remained above plasma and saliva levels during
and after dosing, potentially explaining the continued protection
during lamivudine/raltegravir off PrEP. Our study did not include a
lamivudine-alone arm, limiting the full assessment of the contribu-
tion of raltegravir and lamivudine in the increased activity of the
combination compared with both drugs alone. However, our data
support that the combination regimen is more ‘forgiving’ than ral-
tegravir alone and perhaps more suitable for daily or even on-de-
mand PrEP. Further studies evaluating the activity of raltegravir/
lamivudine at short timepoints post-dosing will be required to fully
confirm the potential of this drug combination for on-demand
PrEP.
The high raltegravir level in rectal tissue and prolonged
presence shows that it accumulated in the tissue and suggests
that, following oral dosing, it was absorbed into the circulation. In
addition, raltegravir may accumulate within the rectum directly as
unabsorbed drug carried in faeces or excreted in a conjugated
form by the bile duct and de-conjugates in the large bowel back to
raltegravir.
Macaque studies had shown that the luteal phase is associated
with increased risk of vaginal HIV transmission;35 however, in
our study the luteal phase could not be confirmed for all female
participants and no correlation was established with PK/PD results.
All baseline rectal explants were reproducibly infected
with high and low challenge titres, except in two participants:
for the first, no productive infection was observed; for the se-
cond, explants cut for the high challenge titre were too small.
All baseline vaginal explants challenged with the high viral titre
were infected; however, only 13 of a total of 18 explants were
productively infected with the low titre at baseline. Consistent
with histological and immunological differences,36 maximum
p24 concentrations were 1 log greater in rectal than in vaginal
explants.
Higher levels of raltegravir in rectal tissue compared with
vaginal tissue did not correlate with higher ex vivo protection
in rectal explants. However, during oral dosing with raltegravir
400 mg!lamivudine 150 mg, a greater protection level against
ex vivo challenge in rectal tissue than in vaginal tissue reflected
higher concentrations of raltegravir and lamivudine measured
in rectal samples compared with vaginal specimens, resulting in
a statistically significant negative correlation between
Figure 3. Longitudinal analysis of protection level. Ex vivo protection of rectal and vaginal explants was defined as day 15 p24 level >60% lower com-
pared with day 15 p24 of baseline explants following challenge with HIV-1BaL at a high titre (10
4 TCID50/mL) (a and b) or a low titre (10
2 TCID50/mL)
(c and d). Data are the percentage of samples considered protected under this criterion at each timepoint on and off PrEP with raltegravir 400 mg (a
and c) and raltegravir 400 mg!lamivudine 150 mg (b and d). The dotted line indicates the timepoint when PrEP dosing stopped. RAL, raltegravir; 3TC,
lamivudine.
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Figure 4. Correlations of drug concentrations with p24 levels in culture supernatants. Log-transformed p24 levels in day 15 culture supernatants
of rectal (a, b, c, d, e, f, m, n, o, p, q and r) and vaginal (g, h, i, j, k, l, s, t, u, v, w and x) explants challenged ex vivo with HIV-1BaL at a high titre (10
4
TCID50/mL) or a low titre (10
2 TCID50/mL) were correlated with log-transformed raltegravir and lamivudine concentrations in plasma and mucosal
tissue (rectal tissue or vaginal tissue) by Pearson correlation. P < 0.05 was considered statistically significant. RAL, raltegravir; 3TC, lamivudine; RT,
rectal tissue; VT, vaginal tissue.
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raltegravir and lamivudine concentrations and p24 levels in rec-
tal tissue. Hence, the raltegravir/lamivudine combination main-
tained protection in a broader range of tissue and for longer
compared with raltegravir alone, conferring protection for
5 days after stopping PrEP. The lack of statistically significant
PK/PD correlations in vaginal tissue (at high viral titres) could be
due to insufficient drug levels in HIV target cells within the tis-
sue to inhibit viral replication or to tissue-specific factors such as
cellular activation level and microbiota. In contrast, drug con-
centrations may exceed the required levels for inhibition in tis-
sues subjected to a low viral challenge titre, thereby preventing
the establishment of a concentration–effect relationship.
Currently the ex vivo challenge of mucosal explants remains
the only practical way to address PD in humans, aside from Phase
III trials, and provides an important tool for risk reduction of
late-stage failure when selecting drug strategies for large studies.
The close correlation of drug levels between saliva and plasma
indicates that non-invasive saliva sampling could be used to
monitor adherence for people on PrEP or HIV treatment taking
raltegravir and/or lamivudine.
To the best of our knowledge, this is the first report of the
protective activity of raltegravir as an oral PrEP candidate where
longitudinal sampling for each participant has been conducted
using samples at baseline as their own control and confirms that it
is rapidly absorbed with greater accumulation in rectal tissue than
in vaginal tissue. Pharmacological boosting of raltegravir with la-
mivudine resulted in greater and more prolonged protection
against ex vivo challenge of rectal and vaginal tissues without a
change in drug levels of raltegravir in these compartments.
Hence, lamivudine continues to show promise as a PrEP agent.
Therefore, the raltegravir 400 mg!lamivudine 150 mg regimen is
a potential PrEP candidate for people who are unable to take
tenofovir-based PrEP.
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